37 results about "Enzymic degradation" patented technology

The invention relates to a method for preparing cassava polysaccharide iron. The method is to oxidize and degrade cassava starch with hydrogen oxide to obtain an applicable oligosaccharide solution, and then add ferric chloride and sodium hydroxide solution dropwise to perform a complex reaction to obtain cassava polysaccharide. The iron synthesis solution is then filtered to remove water-insoluble impurities to obtain cassava polysaccharide iron solution, which is then desalinated and concentrated by ultrafiltration membrane technology, spray dried or vacuum evaporated, dried and crushed, and finally cassava polysaccharide iron products are obtained. The present invention uses hydrogen peroxide to oxidize and degrade cassava starch to replace the previous acid or enzymatic degradation process, which not only can significantly reduce the generation of by-product glucose than the acid method, obtain a higher yield of applicable oligosaccharides, and is more efficient than the enzymatic method. The degradation time is greatly shortened, thereby reducing production costs; it also replaces the previous ethanol or methanol solvent method to remove sodium chloride, avoids the use of flammable and explosive materials such as ethanol or methanol, and eliminates hidden dangers in production safety. The cassava polysaccharide iron prepared by the invention can be used as an iron supplement for poultry and livestock.

The invention discloses a tumor antigen TRAG-3 mimic epitope peptide and an application thereof. The mimic epitope peptide comprises an amino acid sequence shown by Ile-Leu-Leu-Arg-Asp-Ala-Gly-Leu-Val, wherein the fifth Asp is D-Asp or the sixth Ala is D-Ala. The mimic epitope peptide has the advantages of better enzymic degradation resistant stability compared with TRAG-3 natural epitope peptide, stronger appetency compared with HLA-A2.1, and stronger CTL specific killing effect compared with TRAG-3 positive tumor cells, can be used for preparing polypeptide vaccine for treating the TRAG-3 positive tumor cells, and has good development and application prospect in the immunotherapy filed.